Gepotidacin

95 interactions 6 explained in plain English

Also sold as: Blujepa

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Ketoconazole Topical Nafcillin Injection Famotidine Injection Dihydroergotamine Injection Disopyramide Oxaliplatin Injection

1 Contraindicated 92 Major 2 Moderate

All (95) Contraindicated (1) Major (92) Moderate (2)

Contraindicated

Gepotidacin Ketoconazole Topical Extina® Foam Increased CYP3A4 substrate exposure and an increased risk of QT interval prolongation Details

Major

Gepotidacin Clindamycin ANTIROBE Explained Increased CYP3A4 substrate with NTI exposure Details Gepotidacin Amitriptyline Elavil Explained An increased risk of QT interval prolongation Details Gepotidacin Sertraline Explained An increased risk of QT interval prolongation Details Gepotidacin Buprenorphine Belbuca Explained An increased risk of QT interval prolongation Details Gepotidacin Colchicine Colcrys Explained Increased CYP3A4 substrate with NTI exposure Details Gepotidacin Abemaciclib Verzenio Explained Increased CYP3A4 substrate with NTI exposure Details Gepotidacin Acalabrutinib Calquence Increased CYP3A4 substrate with NTI exposure Details Gepotidacin Amisulpride Injection Barhemsys An increased risk of QT interval prolongation Details Gepotidacin Arsenic Trioxide Trisenox An increased risk of QT interval prolongation Details Gepotidacin Aripiprazole Injection Abilify An increased risk of QT interval prolongation Details Gepotidacin Arsenic Trioxide Injection Trisenox An increased risk of QT interval prolongation Details Gepotidacin Asenapine Transdermal Patch Secuado An increased risk of QT interval prolongation Details Gepotidacin Azithromycin AzaSite An increased risk of QT interval prolongation Details Gepotidacin Alfuzosin UroXatral An increased risk of QT interval prolongation Details Gepotidacin Anagrelide Agrylin An increased risk of QT interval prolongation Details Gepotidacin Axitinib Inlyta Increased CYP3A4 substrate with NTI exposure Details Gepotidacin Bedaquiline Sirturo An increased risk of QT interval prolongation Details Gepotidacin Bosutinib Bosulif Increased CYP3A4 substrate with NTI exposure Details Gepotidacin Brigatinib Alunbrig Increased CYP3A4 substrate with NTI exposure Details Gepotidacin Chloroquine Aralen® An increased risk of QT interval prolongation Details Gepotidacin Clindamycin Injection ANTIROBE Increased CYP3A4 substrate with NTI exposure Details Gepotidacin Clindamycin Topical C/T/S® Increased CYP3A4 substrate with NTI exposure Details Gepotidacin Clindamycin Vaginal Cleocin Increased CYP3A4 substrate with NTI exposure Details Gepotidacin Cobimetinib Cotellic Increased CYP3A4 substrate with NTI exposure Details Gepotidacin Cyclosporine Injection Atopica Increased CYP3A4 substrate with NTI exposure Details Gepotidacin Cyclosporine Ophthalmic Cequa Increased CYP3A4 substrate with NTI exposure Details Gepotidacin Dasatinib Phyrago Increased CYP3A4 substrate with NTI exposure and an increased risk of QT interval prolongation Details Gepotidacin Degarelix Injection Firmagon An increased risk of QT interval prolongation Details Gepotidacin Deutetrabenazine Austedo An increased risk of QT interval prolongation Details Gepotidacin Dexamethasone Injection Decadron Reduced gepotidacin exposure Details Gepotidacin Dexamethasone Ophthalmic Dexacidin® (as a combination product containing Dexamethasone, Neomycin, Polymyxin B) Reduced gepotidacin exposure Details Gepotidacin Digoxin Cardoxin® Increased digoxin exposure Details Gepotidacin Dihydroergotamine Injection DHE-45® Injection Increased CYP3A4 substrate with NTI exposure Details Gepotidacin Dihydroergotamine Nasal Spray Migranal Increased CYP3A4 substrate with NTI exposure Details Gepotidacin Disopyramide Norpace An increased risk of QT interval prolongation Details Gepotidacin Docetaxel Beizray Increased CYP3A4 substrate with NTI exposure Details Gepotidacin Docetaxel Injection Beizray Increased CYP3A4 substrate with NTI exposure Details Gepotidacin Dofetilide Tikosyn Increased CYP3A4 substrate with NTI exposure and an increased risk of QT interval prolongation Details Gepotidacin Dolasetron Anzemet An increased risk of QT interval prolongation Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.